Compare GOTU & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GOTU | CBIO |
|---|---|---|
| Founded | 2014 | 2003 |
| Country | China | United States |
| Employees | N/A | 44 |
| Industry | Other Consumer Services | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 469.8M | 557.8M |
| IPO Year | 2019 | N/A |
| Metric | GOTU | CBIO |
|---|---|---|
| Price | $1.94 | $18.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $26.67 |
| AVG Volume (30 Days) | ★ 319.0K | 297.1K |
| Earning Date | 05-15-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.33 | N/A |
| Revenue Next Year | $13.02 | $279.20 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.84 | $8.72 |
| 52 Week High | $4.12 | $27.41 |
| Indicator | GOTU | CBIO |
|---|---|---|
| Relative Strength Index (RSI) | 47.86 | 44.96 |
| Support Level | $1.86 | $10.83 |
| Resistance Level | $2.04 | $20.58 |
| Average True Range (ATR) | 0.05 | 2.53 |
| MACD | 0.01 | -0.85 |
| Stochastic Oscillator | 51.72 | 24.32 |
Gaotu Techedu Inc is a technology-driven education company that provides online live courses in a large-class setting backed by its proprietary technology infrastructure. The company offers courses in large-class format, which amplifies the benefits of online education and allows it to rapidly expand its student base. It operates solely in the PRC and all assets are located in the PRC. The learning services that the company offers include Traditional Learning Services, Non-Academic Tutoring Services, and College Student and Adult Education Services. It derives maximum revenue from Learning Services and also from Educational content & digitalized learning products.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.